Tumor B
necrosis I
factor I
alpha I
( I
TNF-alpha I
) I
mRNA I
production O
was O
analyzed O
by O
polymerase O
chain O
reaction O
amplification O
in O
monocytic O
U937 O
cells O
and O
in O
a O
chronically O
HIV O
infected O
U937 O
cell O
line O
( O
U9-IIIB O
) O
. O

TNF-alpha B
RNA I
was O
undetectable O
in O
U937 O
cells O
, O
whereas O
a O
low O
constitutive O
level O
was O
detected O
in O
U9-IIIB O
cells O
. O

Paramyxovirus O
infection O
induced O
a O
5- O
to O
10-fold O
increase O
in O
the O
steady-state O
level O
of O
TNF-alpha B
RNA I
in O
U9-IIIB O
cells O
compared O
with O
U937 O
cells O
, O
suggesting O
that O
HIV-infected O
monocytic O
cells O
produced O
higher O
levels O
of O
TNF-alpha O
than O
did O
normal O
cells O
after O
a O
secondary O
virus O
infection O
. O

This O
level O
of O
NF-kappa O
B O
-independent O
activity O
appears O
to O
be O
sufficient O
for O
virus O
multiplication O
, O
since O
TNF-alpha O
treatment O
had O
no O
effect O
on O
the O
kinetics O
of O
de O
novo O
HIV O
type O
1 O
( O
HIV-1 O
) O
infection O
and O
viral B
RNA I
production O
in O
U937 O
cells O
. O

However O
, O
in O
Jurkat O
cells O
, O
TNF-alpha O
dramatically O
enhanced O
the O
spread O
of O
HIV-1 O
through O
the O
cell O
population O
and O
increased O
viral B
RNA I
synthesis O
, O
indicating O
that O
in O
T O
cells O
HIV-1 O
multiplication O
was O
stimulated O
by O
TNF-alpha O
treatment O
. O

This O
stimulation O
of O
HIV-1 O
production O
is O
correlated O
with O
an O
increase O
in O
the O
level O
of O
HIV-1 B
RNA I
and O
and O
activation O
of O
NF-kappa O
B O
. O

The O
binding O
sites O
and O
partial O
proteolysis O
profile O
of O
this O
protein O
are O
indistinguishable O
from O
those O
of O
the O
erythroid O
protein O
; O
also O
, O
NF-E1 B
messenger I
RNA I
is O
the O
same O
size O
in O
both O
the O
megakaryocytic O
and O
erythroid O
cell O
lines O
. O

We O
show O
that O
in O
the O
human O
T O
lymphoblastic O
tumor O
cell O
line O
Molt4 B
c-myc I
mRNA I
and O
protein O
expression O
is O
down-regulated O
after O
exposure O
to O
dimethyl O
sulfoxide O
, O
to O
phorbol O
myristate O
acetate O
, O
or O
to O
the O
calcium O
ionophore O
A23187 O
, O
which O
raises O
the O
intracellular O
calcium O
concentration O
. O

c-myc B
RNA I
, O
which O
is O
constitutively O
expressed O
in O
RWLeu-4 O
cells O
, O
increased O
after O
0.5 O
h O
of O
treatment O
with O
50 O
nM O
VD3 O
and O
then O
rapidly O
decreased O
to O
barely O
detectable O
levels O
after O
4 O
h O
of O
treatment O
. O

In O
a O
series O
of O
functional O
studies O
we O
found O
that O
modulation O
of O
the O
level O
of O
the O
mRNAs B
coding O
for O
both O
the O
c-myc O
oncogene O
and O
the O
growth O
factor O
known O
as O
granulocyte-monocyte O
colony O
stimulating O
activity O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
correlated O
with O
the O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor O
status O
of O
these O
cells O
. O

Low O
levels O
of O
c-jun B
transcripts I
were O
detectable O
in O
untreated O
HL-60 O
leukemic O
cells O
, O
increased O
significantly O
by O
6 O
h O
, O
and O
reached O
near O
maximal O
levels O
by O
24 O
h O
of O
exposure O
to O
32 O
nM O
TPA O
. O

The O
half-life O
of O
c-jun B
RNA I
as O
determined O
by O
treating O
HL-60 O
cells O
with O
TPA O
and O
actinomycin O
D O
was O
30 O
min O
. O

In O
contrast O
, O
the O
half-life O
of O
c-jun B
RNA I
in O
TPA-treated O
HL-60 O
cells O
exposed O
to O
cycloheximide O
and O
actinomycin O
D O
was O
greater O
than O
2 O
h O
. O

These O
findings O
suggested O
that O
the O
increase O
in O
c-jun B
RNA I
observed O
during O
TPA-induced O
monocytic O
differentiation O
is O
mediated O
by O
both O
transcriptional O
and O
post-transcriptional O
mechanisms O
. O

Mammalian O
cells O
express O
two O
distinct O
forms O
of O
transcription O
factor O
CREB O
( O
cAMP O
response O
element O
binding O
protein O
) O
that O
are O
apparently O
the O
products O
of O
alternative O
splicing O
of O
the O
CREB B
gene I
transcript I
. O

Many O
of O
these O
may O
be O
created O
by O
alternative O
splicing O
of O
a O
primary B
transcript I
of O
one O
Oct O
factor O
gene O
and O
may O
serve O
a O
specific O
function O
in O
the O
fine O
tuning O
of O
gene O
expression O
. O

RNA O
from O
control O
resting O
cells O
contained O
low O
to O
undetectable O
levels O
of O
c-jun B
, O
fibronectin B
receptor I
, O
and O
actin B
mRNA I
. O

In O
contrast O
, O
the O
expression O
of O
actin B
and I
fibronectin I
receptor I
mRNA I
was O
more O
sustained O
, O
and O
the O
expression O
of O
these O
genes O
remained O
elevated O
at O
24 O
to O
48 O
h O
after O
M-CSF O
addition O
. O

Adherence-dependent O
increase O
in O
human B
monocyte I
PDGF I
( I
B I
) I
mRNA I
is O
associated O
with O
increases O
in O
c-fos B
, I
c-jun I
, I
and I
EGR2 I
mRNA I
. O

We O
hypothesized O
that O
adherence O
itself O
might O
be O
an O
important O
trigger O
for O
a O
sequence O
of O
gene O
activation O
culminating O
in O
cells O
with O
increased O
mRNA B
encoding O
profibrotic O
growth O
factors O
such O
as O
platelet-derived O
growth O
factor O
B O
subunit O
( O
PDGF O
[ O
B O
] O
) O
and O
transforming O
growth O
factor-beta O
( O
TGF-beta O
) O
. O

After O
in O
vitro O
adherence O
, O
human O
monocytes O
had O
a O
biphasic O
increase O
in O
PDGF B
( I
B I
) I
mRNA I
with O
peaks O
at O
6 O
h O
and O
13 O
d O
. O

No O
increase O
in O
TGF-beta B
mRNA I
was O
observed O
. O

The O
6-h O
increase O
in O
PDGF B
( I
B I
) I
mRNA I
was O
adherence O
dependent O
, O
and O
in O
addition O
, O
was O
abrogated O
when O
the O
cytoskeletal O
integrity O
was O
compromised O
by O
cytochalasin O
D O
. O

The O
6-h O
increase O
in O
PDGF B
( I
B I
) I
mRNA I
was O
unaltered O
by O
adherence O
in O
the O
presence O
of O
the O
monocyte O
stimulus O
lipopolysaccharide O
. O

Adherence O
to O
either O
fibronectin O
or O
collagen-coated O
plastic O
had O
little O
consistent O
effect O
on O
PDGF B
( I
B I
) I
mRNA I
accumulation O
. O

The O
increased O
PDGF B
( I
B I
) I
mRNA I
observed O
in O
adherent O
monocytes O
was O
accompanied O
by O
increases O
in O
mRNAs B
of O
the O
early O
growth O
response O
genes O
c-fos O
( O
maximal O
at O
20 O
min O
) O
, O
c-jun O
, O
and O
EGR2 O
( O
maximal O
at O
6-24 O
h O
) O
. O

These O
observations O
suggest O
that O
adherence O
results O
in O
increases O
of O
c-fos B
, I
c-jun I
, I
EGR2 I
, I
and I
PDGF I
( I
B I
) I
mRNA I
. O

In O
Northern O
blot O
analysis O
, O
mRNA B
species I
of O
approximately O
1.8 O
kilobases O
that O
hybridized O
with O
human O
FKBP O
cDNA O
were O
detected O
in O
poly B
( I
A I
) I
+ I
RNAs I
from O
brain O
, O
lung O
, O
liver O
, O
and O
placental O
cells O
and O
leukocytes O
. O

Induction O
of O
Jurkat O
leukemic O
T O
cells O
with O
phorbol O
12-myristate O
13-acetate O
and O
ionomycin O
did O
not O
affect O
the O
level O
of O
FKBP B
mRNA I
. O

A O
significant O
proportion O
of O
transcripts B
appear O
to O
terminate O
prematurely O
in O
the O
absence O
of O
transactivators O
. O

Using O
constructs O
in O
which O
mRNA B
production O
controlled O
by O
a O
specific O
transcription O
factor O
could O
be O
readily O
measured O
we O
found O
that O
both O
cyclosporin O
A O
and O
FK506 O
completely O
inhibited O
transcription O
activated O
by O
NF-AT O
, O
NFIL2 O
A O
, O
NFIL2 O
B O
and O
partially O
inhibited O
transcription O
activated O
by O
NF O
kappa O
B O
. O

However O
, O
cyclosporin O
A O
and O
FK506 O
did O
not O
inhibit O
Ca2+ O
mobilization O
dependent O
expression O
of O
c-fos B
mRNA I
indicating O
that O
only O
a O
subset O
of O
signalling O
pathways O
regulated O
by O
Ca2+ O
is O
sensitive O
to O
these O
drugs O
. O

Rex O
acts O
posttranscriptionally O
to O
facilitate O
accumulation O
of O
full-length O
gag/pol O
and O
singly O
spliced O
env B
mRNA I
in O
the O
cytoplasm O
of O
HTLV-infected O
cells O
. O

However O
, O
in O
vitro O
mutagenesis O
of O
the O
HTLV-I O
rex O
gene O
has O
provided O
indirect O
evidence O
which O
suggests O
that O
p21rex O
, O
and O
by O
analogy O
HTLV-II O
p24rex O
, O
results O
from O
initiation O
at O
an O
internal O
AUG O
of O
the O
tax/rex B
mRNA I
. O

Protein O
kinase O
inhibitor O
H-7 O
blocks O
accumulation O
of O
unspliced B
mRNA I
of O
human O
T-cell O
leukemia O
virus O
type O
I O
( O
HTLV-I O
) O
. O

Rex O
, O
the O
post-transcriptional O
regulator O
of O
human O
T-cell O
leukemia O
virus O
type O
I O
( O
HTLV-I O
) O
, O
is O
known O
to O
induce O
accumulation O
of O
the O
unspliced B
viral I
gag-pol I
mRNA I
. O

Treatment O
of O
an O
HTLV-I O
infected O
human O
T-cell O
line O
with O
H-7 O
blocked O
specifically O
accumulation O
of O
the O
unspliced B
gag-pol I
mRNA I
, O
resulting O
in O
the O
decreased O
Gag O
protein O
synthesis O
that O
corresponds O
with O
the O
decreased O
in O
vivo O
phosphorylation O
of O
Rex O
. O

We O
have O
identified O
two O
human O
pre-B-cell O
lines O
that O
contain O
extremely O
low O
levels O
of O
OTF-2 O
yet O
still O
express O
high O
levels O
of O
steady-state B
immunoglobulin I
heavy-chain I
mRNA I
in O
vivo O
and O
efficiently O
transcribe O
an O
immunoglobulin O
gene O
in O
vitro O
. O

( O
iii O
) O
LMP1 O
expression O
in O
Daudi O
and O
P3HR-1-infected O
cells O
was O
controlled O
at O
the O
mRNA B
level O
, O
and O
EBNA-2 O
expression O
in O
Daudi O
cells O
increased O
LMP1 B
mRNA I
. O

Heat O
shock O
caused O
an O
increase O
in O
c-fos O
and O
c-jun O
mRNA O
levels O
and O
a O
decrease O
in O
c-myc B
mRNA I
levels O
in O
pre-B O
( O
Hyon O
) O
and O
T O
( O
DND-41 O
) O
cell O
lines O
as O
well O
as O
in O
freshly O
isolated O
normal O
human O
thymocytes O
. O

Secondarily O
, O
heat O
shock O
of O
Hyon O
cells O
stabilized O
the O
c-myc B
mRNA I
level O
by O
increasing O
its O
half-life O
from O
24 O
to O
45 O
min O
. O

The O
overall O
effect O
of O
heat O
shock O
on O
c-myc B
mRNA I
level O
, O
however O
, O
was O
a O
marked O
inhibition O
of O
its O
transcription O
. O

CD16 O
( O
Fc O
gamma O
RIIIA O
) O
-induced O
expression O
of O
cytokine B
mRNA I
in O
NK O
cells O
occurs O
via O
a O
CsA-sensitive O
and O
Ca O
( O
2+ O
) O
-dependent O
mechanism O
. O

NK O
cells O
do O
not O
express O
NFATc O
constitutively O
, O
but O
NFATc B
mRNA I
accumulation O
is O
induced O
in O
these O
cells O
within O
2 O
h O
of O
stimulation O
with O
CD16 O
ligands O
. O

These O
results O
provide O
the O
first O
direct O
evidence O
that O
both O
CsA-sensitive O
transcription O
factors O
, O
NFATp O
and O
NFATc O
, O
are O
expressed O
in O
human O
NK O
cells O
, O
and O
that O
their O
activation O
and/or O
expression O
can O
be O
regulated O
in O
primary O
cells O
by O
a O
single O
stimulus O
, O
that O
, O
in O
the O
case O
of O
CD16 O
in O
NK O
cells O
, O
results O
in O
early O
activation O
of O
NFATp O
and O
subsequently O
induced O
expression O
of O
NFATc B
mRNA I
. O

This O
study O
evaluates O
( O
i O
) O
constitutive O
levels O
of O
oncogene O
and O
p53 B
transcripts I
in O
chronic O
phase O
CML O
patients O
and O
( O
ii O
) O
their O
modulations O
subsequent O
to O
in O
vivo O
therapy O
with O
rIFN-alpha O
2c O
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c-fos B
transcript I
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN-alpha O
therapy O
( O
p O
< O
0.01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0.6895 O
, O
p O
< O
0.01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
-0.568 O
, O
p O
< O
0.01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive B
mRNA I
levels O
of O
the O
hybrid O
bcr/abl O
, O
c-myc O
and O
p53 O
are O
positively O
correlated O
with O
each O
other O
, O
but O
failed O
to O
relate O
to O
disease O
parameters O
, O
and O
( O
iii O
) O
acute O
and O
chronic O
in O
vivo O
exposure O
to O
IFN-alpha O
is O
accompanied O
by O
upregulation O
of O
c-fos O
and O
downregulation O
of O
c-myc B
mRNA I
levels O
in O
responder O
patients O
. O

Hematopoietic O
tissues O
from O
these O
mice O
display O
elevated O
levels O
of O
both O
nuclear O
NF-kappa O
B O
and O
mRNAs B
of O
some O
, O
but O
not O
all O
, O
genes O
thought O
to O
be O
regulated O
by O
NF-kappa O
B O
. O

Microtubule O
disruption O
totally O
abolished O
the O
ability O
of O
exogenous O
1 O
, O
25 O
( O
OH O
) O
2D3 O
to O
suppress O
its O
own O
synthesis O
and O
to O
induce O
24-hydroxylase B
mRNA I
and O
activity O
, O
without O
affecting O
either O
total O
1 O
, O
25 O
( O
OH O
) O
2D3 O
uptake O
or O
maximal O
1 O
, O
25 O
( O
OH O
) O
2D3 O
-VDR O
binding O
. O

Our O
studies O
provide O
an O
explanation O
for O
a O
previous O
observation O
that O
TCRG B
mRNA I
levels O
, O
but O
not O
mRNA O
levels O
for O
T O
cell O
receptor O
alpha O
and O
-beta O
, O
are O
increased O
by O
ionomycin O
treatment O
. O

The O
B4-2 O
clone O
coded O
for O
an O
mRNA B
of O
2061 O
bp O
in O
length O
. O

An O
Epstein-Barr O
virus O
( O
EBV O
) O
-transformed O
cell O
line O
derived O
from O
her O
lymphocytes O
had O
normal O
gamma O
c O
expression O
but O
lacked O
Jak3 O
protein O
and O
had O
greatly O
diminished O
Jak3 B
messenger I
RNA I
. O

To O
understand O
the O
mechanism O
of O
leukemic O
cell O
infiltration O
into O
organs O
, O
we O
studied O
the O
expression O
and O
regulation O
of O
L-selectin B
mRNA I
in O
fresh O
leukemic O
cells O
of O
adult O
T-cell O
leukemia O
( O
ATL O
) O
patients O
and O
investigated O
the O
response O
of O
the O
L-selectin O
promoter O
to O
human O
T-cell O
lymphotropic O
virus O
type O
1 O
( O
HTLV-1 O
) O
Tax O
, O
which O
is O
a O
viral O
transcriptional O
transactivator O
. O

Northern O
blot O
analysis O
showed O
that O
ATL O
cells O
overexpressed O
that O
L-selectin B
mRNA I
and O
that O
the O
level O
was O
aberrantly O
upregulated O
after O
PMA O
stimulation O
. O

Studies O
using O
in O
situ O
hybridization O
showed O
expression O
of O
the O
L-selectin B
mRNA I
in O
the O
infiltrating O
leukemic O
cells O
in O
the O
liver O
of O
two O
ATL O
patients O
. O

The O
induction O
of O
Tax O
expression O
in O
JPX9 O
cells O
resulted O
in O
about O
a O
twofold O
increase O
in O
the O
mRNA B
expression O
levels O
compared O
with O
the O
basal O
level O
. O

Evidence O
for O
normal O
vitamin B
D I
receptor I
messenger I
ribonucleic I
acid I
and O
genotype O
in O
absorptive O
hypercalciuria O
. O

The O
coding O
region O
of O
VDR B
messenger I
RNA I
was O
also O
normal O
, O
as O
determined O
by O
both O
DNA O
sequence O
analysis O
and O
chemical O
mismatch O
cleavage O
analysis O
of O
copy O
DNA O
from O
11 O
index O
absorptive O
hypercalciuric O
patients O
. O

The O
exon-intron O
structure O
of O
the O
5 O
' O
portion O
of O
the O
thromboxane O
receptor O
gene O
was O
determined O
initially O
by O
comparing O
the O
nucleotide O
sequence O
of O
the O
5 O
' O
flanking O
genomic O
clone O
with O
that O
of O
a O
novel O
human O
uterine O
thromboxane O
receptor O
cDNA O
that O
extended O
the O
mRNA B
141 O
bp O
further O
upstream O
than O
the O
previously O
identified O
human O
placental O
cDNA O
. O

NF-IL6 B
mRNA I
was O
found O
in O
human O
Jurkat O
T O
cells O
and O
in O
the O
mouse O
Th2 O
clone O
D10 O
, O
but O
not O
in O
Th1 O
clone O
29 O
. O

TCF-1 B
mRNA I
was O
originally O
found O
to O
be O
expressed O
in O
a O
T O
cell-specific O
fashion O
within O
a O
set O
of O
human O
and O
mouse O
cell O
lines O
. O

Here O
we O
report O
that O
cross-linking O
of O
Fc O
gamma O
RI O
or O
Fc O
gamma O
RII O
by O
adherent O
human O
IgG O
or O
by O
specific O
anti-Fc O
gamma O
R O
mAb O
activates O
HIV-1 O
gene O
expression O
in O
the O
human O
monocytic O
cell O
line O
BF24 O
and O
increased O
HIV B
RNA I
expression O
in O
monocytes O
from O
HIV O
infected O
patients O
as O
assayed O
by O
reverse O
transcription-PCR O
. O

In O
contrast O
, O
enhancement O
of O
IL-2 B
mRNA I
expression O
in O
neonates O
was O
similar O
to O
adult O
levels O
. O

The O
cellular O
mechanism O
governing O
the O
diminished O
proliferative O
response O
of O
neonatal O
T O
lymphocytes O
to O
anti-CD2 O
may O
therefore O
be O
due O
to O
decreased O
NF O
kappa O
B O
induction O
, O
reduced O
IL-2 B
mRNA I
expression O
and O
deficient O
IL-2 O
production O
. O

We O
have O
analyzed O
the O
expression O
of O
TCL1 B
mRNA I
and O
protein O
in O
peripheral O
blood O
lymphocytes O
( O
PBLs O
) O
from O
four O
AT O
cases O
and O
from O
healthy O
controls O
. O

Quantitation O
of O
beta B
1 I
triiodothyronine I
receptor I
mRNA I
in O
human O
tissues O
by O
competitive O
reverse O
transcription O
polymerase O
chain O
reaction O
. O

Total O
RNA O
was O
isolated O
from O
peripheral O
blood O
mononuclear O
cells O
and O
hTR B
beta I
1 I
mRNA I
levels O
determined O
by O
quantitative O
competitive O
reverse O
transcription O
PCR O
. O

For O
comparison O
, O
hTR B
beta I
1 I
mRNA I
levels O
were O
determined O
in O
lymphocytes O
and O
normal O
thyroid O
tissue O
of O
euthyroid O
patients O
. O

Human B
TR I
beta I
1 I
mRNA I
levels O
in O
lymphocytes O
were O
1.8 O
+/- O
0.4 O
, O
1.9 O
+/- O
0.5 O
, O
1.1 O
+/- O
0.4 O
10 O
( O
-18 O
) O
mol/microgram O
RNA O
in O
hypo- O
, O
eu O
-and O
hyperthyroid O
patients O
, O
respectively O
, O
corresponding O
to O
an O
estimated O
0.5 O
-2 O
molecules O
per O
cell O
. O

Although O
the O
mean O
hTR B
beta I
1 I
mRNA I
levels O
were O
40 O
% O
lower O
in O
hyperthyroid O
than O
in O
euthyroid O
subjects O
, O
this O
difference O
did O
not O
reach O
statistical O
significance O
. O

Similar O
levels O
of O
hTR B
beta I
1 I
mRNA I
levels O
were O
detected O
in O
thyroid O
gland O
from O
euthyroid O
patients O
. O

In O
summary O
, O
we O
developed O
an O
assay O
for O
the O
quantitative O
determination O
of O
hTR B
beta I
1 I
mRNA I
levels O
in O
small O
human O
tissue O
samples O
, O
containing O
as O
little O
as O
50 O
ng O
of O
total O
RNA O
. O

Absolute O
hTR B
beta I
1 I
mRNA I
levels O
are O
very O
low O
with O
an O
estimated O
one O
molecule O
of O
mRNA B
being O
present O
in O
a O
mononuclear O
blood O
cell O
or O
thyrocyte O
. O

However O
, O
there O
is O
a O
non-significant O
trend O
towards O
a O
down-regulation O
of O
hTR B
beta I
1 I
mRNA I
levels O
in O
hyperthyroid O
patients O
. O

PU.1 B
mRNA I
expression O
and O
PU.1 O
DNA O
binding O
activity O
, O
as O
measured O
by O
Northern O
blot O
analysis O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
were O
evident O
in O
cell O
lines O
representing O
pro-B O
, O
pre-B O
, O
and O
mature O
B O
cells O
. O

CsA O
similarly O
mediated O
a O
reduction O
of O
up O
to O
65 O
% O
in O
GM-CSF B
mRNA I
and O
protein O
expression O
in O
activated O
endothelial O
cells O
. O

Regulation O
of O
c-jun B
mRNA I
expression O
by O
hydroxyurea O
in O
human O
K562 O
cells O
during O
erythroid O
differentiation O
[ O
published O
erratum O
appears O
in O
Biochim O
Biophys O
Acta O
1995 O
Dec O
27 O
; O
1264 O
( O
3 O
) O
: O
409 O
] O

The O
levels O
of O
c-jun B
mRNA I
was O
elevated O
4 O
to O
7.5-fold O
by O
HU O
within O
2 O
h O
. O

Both O
nuclear O
run-on O
and O
actinomycin O
D O
pulse O
experiments O
strongly O
indicate O
that O
HU O
regulates O
c-jun B
mRNA I
expression O
by O
increasing O
the O
rate O
of O
synthesis O
as O
well O
as O
stabilizing O
the O
c-jun B
mRNA I
. O

In O
vitro O
treatment O
of O
a O
monocyte/macrophage O
cell O
line O
with O
CCl4 O
led O
to O
enhanced O
NF-kappa O
B O
binding O
and O
an O
increase O
in O
tumor B
necrosis I
factor-alpha I
( I
TNF-alpha I
) I
messenger I
RNA I
levels O
. O

Cysteamine O
treatment O
inhibited O
both O
expression O
of O
the O
IL-2 B
mRNA I
and O
secretion O
of O
IL-2 O
into O
the O
culture O
medium O
. O

We O
examined O
by O
northern O
hybridization O
the O
expression O
of O
Id2 B
and I
Id3 I
mRNA I
in O
human O
leukemia/lymphoma O
lines O
and O
patient O
samples O
, O
as O
well O
as O
resting O
and O
activated O
normal O
human O
lymphocytes O
from O
peripheral O
blood O
( O
PBL O
) O
. O

The O
Id2 B
mRNA I
was O
abundantly O
expressed O
in O
5/12 O
T-cell O
and O
3/4 O
B-cell O
lines O
, O
and O
Id3 B
mRNA I
was O
detected O
in O
4/12 O
T-cell O
and O
3/4 O
B-cell O
lines O
. O

Interestingly O
, O
Id2 B
, O
but O
not O
Id3 B
, O
mRNA O
was O
strongly O
expressed O
in O
4/5 O
T-cell O
lines O
infected O
with O
human O
T-cell O
leukemia O
virus O
type O
I O
( O
HTLV-I O
) O
( O
ATL-1k O
, O
MT-2 O
, O
S-LB1 O
) O
and O
type O
II O
( O
Mo O
) O
. O

Another O
unexpected O
finding O
was O
that O
T-cell O
leukemias O
and O
T-cell O
lines O
often O
expressed O
either O
Id2 B
or O
Id3 B
mRNA I
. O

In O
addition O
, O
resting O
PBL O
constitutively O
expressed O
prominent O
levels O
of O
Id2 B
mRNA I
, O
but O
not O
Id3 B
mRNA I
. O

Taken O
together O
, O
our O
studies O
revealed O
three O
unexpected O
findings O
which O
require O
further O
analysis O
: O
( O
1 O
) O
expression O
of O
Id2 B
mRNA I
is O
often O
associated O
with O
lymphocytic O
transformation O
by O
HTLV-I O
or O
-II O
; O
( O
2 O
) O
T-cells O
usually O
express O
either O
Id2 O
or O
Id3 B
mRNA I
, O
but O
B-cells O
often O
express O
both O
simultaneously O
; O
( O
3 O
) O
non-dividing O
, O
normal O
PBL O
express O
high O
levels O
of O
Id2 O
and O
no O
Id3 B
mRNA I
; O
and O
with O
the O
onset O
of O
cellular O
proliferation O
, O
levels O
of O
Id2 B
mRNA I
decrease O
while O
levels O
of O
Id3 B
mRNA I
increase O
, O
suggesting O
that O
regulation O
of O
expression O
of O
these O
closely O
related O
genes O
is O
disparate O
. O

Northern O
blot O
analysis O
revealed O
that O
BLR2 B
mRNA I
could O
be O
highly O
stimulated O
in O
mitogen- O
and O
anti-CD3-treated O
peripheral O
blood O
lymphocytes O
. O

BLR2-specific B
mRNA I
could O
be O
detected O
in O
all O
Epstein-Barr O
virus O
positive O
B O
cell O
lines O
. O

